Recruiting
A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild-type RAS and right primary tumour location (right-PTL) - ARIEL-ENGIC 04 EU trial
2025-521209-42-00· Phase 4· Fondazione GONO G.I.· Source
Not yet recruiting
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2
2025-521608-23-00· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Recruiting
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
NCT07722546· Phase 2· Biogen· Source
Recruiting
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer
NCT07659782· Phase 2· Verastem, Inc.· Source
Recruiting
A Long-Term Extension Study of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease.
NCT07596849· Phase 3· argenx· Source
Recruiting
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source
Recruiting
A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033· Phase 3· GlaxoSmithKline· Source
Recruiting
Open Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy.
2025-521640-38-00· Phase 3· Praxis Precision Medicines Inc.· Source
Recruiting
A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)
2024-518296-56-00· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Recruiting
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
NCT06997497· Phase 3· Merck Sharp & Dohme LLC· Source
Recruiting
A Study to Assess the Effectiveness of Second-Line Therapy of Upadacitinib and Risankizumab in Adult Participants With Crohn's Disease in a Real-World Setting
NCT07073079· AbbVie· Source
Active, not recruiting
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
NCT06880744· Phase 3· AbbVie· Source
Recruiting
A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma
NCT06977581· Phase 2· Pfizer· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
NCT06764875· Phase 3· AstraZeneca· Source
Recruiting
An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis
2023-507853-13-00· Phase 2· Eli Lilly & Co.· Source
Recruiting
3TR-PARTNER-RA
2024-511470-79-00· Phase 4· Queen Mary University Of London· Source
Recruiting
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
NCT06227910· Phase 3· Takeda· Source
Recruiting
A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for Adult Participants With Graves' Disease
NCT06727604· Phase 2· Immunovant Sciences GmbH· Source
Recruiting
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
NCT06382948· Phase 3· MedSIR· Source
Active, not recruiting
An open-label study to assess reduction of daily asthma medication with tezepelumab in patients 12 to 80 years of age with severe asthma
2024-512113-41-00· Phase 3· AstraZeneca AB· Source
Recruiting
Steroid withdrawal in SLE
2024-518580-35-00· Phase 4· Azienda Ospedaliero Universitaria Pisana· Source
Active, not recruiting
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319· Phase 2· Sanofi· Source
Recruiting
A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
NCT06541704· Phase 3· Regeneron Pharmaceuticals· Source
Recruiting
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRESECTABLE pMMR AND IMMUNOSCORE IC-HIGH METASTATIC COLORECTAL CANCER PATIENTS. The AtezoTRIBE2 Study
2023-506632-32-00· Phase 3· Fondazione GONO G.I.· Source
Recruiting
Translating Single-cell Vulnerability Into Novel ALS Biomarkers and Therapeutic Targets: Towards a Liquid Nerve Biopsy
NCT07268833· Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta· Source
Enrolling by invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239· Phase 2· Sanofi· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06589986· Phase 3· Hoffmann-La Roche· Source
Recruiting
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
NCT06548542· Phase 2· AbbVie· Source
Recruiting
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
NCT06282575· Phase 3· Jazz Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
NCT06430801· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
A Study Evaluating Pharmacokinetic similarity between ABP 234 and Keytruda® (pembrolizumab) in Subjects with Early-stage Non-squamous Non-small Cell Lung Cancer as Adjuvant Treatment Following Resection and Platinum-based Chemotherapy
2023-508359-38-00· Phase 3· Amgen Inc.· Source
Active, not recruiting
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
NCT06041386· Phase 4· GlaxoSmithKline· Source
Active, not recruiting
Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.
NCT05930275· AbbVie· Source
Active, not recruiting
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· Phase 3· Pfizer· Source
Recruiting
Lynch Syndrome X-Talk of Enteral Mucosa With Immune System
NCT06708429· San Raffaele University· Source
Recruiting
Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients
NCT05817903· Phase 2· Consorzio Oncotech· Source
Active, not recruiting
Efficacy of PErioperative PEmbrolizumab Treatment in Patients With Resectable Metastases From Kidney Cancer
NCT05578664· Phase 2· Consorzio Oncotech· Source
Active, not recruiting
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment
NCT05261399· Phase 3· AstraZeneca· Source
Active, not recruiting
A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT05217446· Phase 2· Pfizer· Source
Recruiting
Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuvant chemotherapy: the ERASE-TMZ study
2024-515681-14-00· Phase 2· Fondazione IRCCS Istituto Nazionale Dei Tumori· Source
Active, not recruiting
Trifluridine/Tipiracil in Combination With Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients.
NCT04564898· Phase 1/2· Gruppo Oncologico del Nord-Ovest· Source
Active, not recruiting
CAPRI 2 GOIM Study: Investigate the Efficacy and Safety of a Bio-marker Driven Cetuximab-based Treatment Regimen
NCT05312398· Phase 2· University of Campania Luigi Vanvitelli· Source
Not yet recruiting
A randomized phase III trial of short-course versus long-course pre-operative chemotherapy with mFOLFIRINOX or PAXG regimen for stage I-III pancreatic ductal adenocarcinoma (PDAC)
2024-519031-42-00· Phase 3· Associazione Italiana Per Lo Studio Del Pancreas· Source
Recruiting
NeoAspMet - Neoadjuvant Aspirin and/or Metformin during preoperative induction chemotherapy and chemoradiotherapy for locally-advanced rectal cancer. A multi-arm, multi-stage, intergroup (STAR-04/SICO-CR01/GISCAD/AIRO-GI) randomised clinical trial. The NeoAspMet trial
2024-519007-10-00· Phase 2/3· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Not yet recruiting
ORGAN SPARING FOR LOCALLY ADVANCED RECTAL CANCER AFTER NEOADJUVANT TREATMENT FOLLOWED BY ELECTROCHEMOTHERAPY - LARC_ DEEP_CANCERS
2024-519050-37-00· Phase 2· IRCCS Istituto Nazionale Tumori Fondazione Pascale· Source
Active, not recruiting
A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
NCT03568318· Phase 3· AbbVie· Source